Getting reimbursement right is what makes a community CAR-T program sustainable. Mastering CAR-T reimbursement and billing is what lets community centers offer these therapies close to home — and build a program that pays for itself as volume grows.
Reimbursement for CAR-T follows a defined sequence, and each step has an owner and a finish line. Centers that map these five steps, confirming coverage, securing authorization, and setting up the right billing codes for the product and the full episode of care, move patients to treatment faster and with far less financial uncertainty. The table below outlines each stage, who is accountable, and what has to be true before the process advances.
| Step | Owner | What Determines Success |
|---|---|---|
| 1. Patient identification and eligibility | Clinical Team | Patient meets the label indication and performance-status criteria, and is documented as such before any payer conversation begins |
| 2. Benefits investigation and coverage verification | Access team | Confirming the plan type (commercial, Medicare, Medicaid, MA), whether the product is a covered benefit, and the patient’s out-of-pocket exposure |
| 3. Prior authorization and medical necessity | Access + MD | A complete submission on the first pass includes prior lines of therapy, diagnostics, and label match, plus a tracked appeal route if denied |
| 4. Payer agreement and terms confirmed | Contracting | Written agreement covering product and full episode. Single-case or outcomes-based, if no contract exists, in place before cells are delivered |
| 5. Claim construction and charge capture | Revenue cycle | Capturing every episode component on the claim under the correct payment mechanism: product acquisition, apheresis, infusion, and toxicity care |
These reimbursement steps run alongside the clinical journey, not separately from it.The figure below places the reimbursement steps in clinical context: the eight stages a patient moves through, where prior authorization applies, and which steps Medicare includes in the CAR-T product payment rather than paying separately. Payer processes vary, so confirm each plan’s requirements.
Some payers may handle CAR-T requests through their routine prior authorization (PA) process, while others may use a dedicated, therapy-specific approach. When requesting coverage for a CAR-T product, it is essential to review the specific payer policies and adhere to their required steps and timeline. This may include contacting a therapy-specific team, submitting dedicated forms, or engaging directly with a case manager.
Including diagnostic and lab tests
Collection of the patient's own cells
For patients requiring additional disease control while awaiting CAR-T product preparation
Genetic modification and expansion of the collected cells
Receipt and preparation of cells for infusion
As needed ahead of dosing — for example, lymphodepletion
Infusion of the CAR-T product
May include treatment of complications and ongoing primary disease management
Medicare includes the bridging, manufacturing, and provider-preparation steps in the drug payment. Other payer processes may vary.
To support reimbursement that appropriately reflects the patient journey, each service must be documented and coded correctly. Inpatient versus outpatient status, as established by the clinician’s written order at each step, drives the required codes, claim requirements, and reimbursement.
Learn more about important Quality context for reimbursement.
QualityYour Payer partners should be included in discussions early in your onboarding process.
Communicate your intent to onboard CAR Ts and start the negotiation process and ensure there is a path to reimbursement
We’re here to help. Reach out today to connect with experts that can guide you.
